Foundayo is Eli Lilly's oral GLP-1, brand name for orforglipron, approved on 1 April 2026 for adults with obesity or overweight with a weight-related condition.1
Two things make it worth its own page. One is how you take it. The other is what it costs, and the pricing here works backwards from everything else on this site.
The convenience is the actual differentiator
Lilly's instruction is four words long:3
Take Foundayo by mouth 1 time each day, with or without food. Swallow tablets whole. Do not break, crush, or chew the tablet.
Eli Lilly
That sounds unremarkable until you compare it with the semaglutide pills. Those require you to take the tablet on an empty stomach with no more than about four ounces of plain water, then wait roughly thirty minutes before eating, drinking or taking anything else. It is a daily ritual that has to fit your morning.
Foundayo has no such ritual because it is a small molecule rather than a peptide, so it does not need the absorption trickery that oral semaglutide depends on. If you have tried a semaglutide pill and quietly given up on the fasting window, this is the difference that matters, more than any figure below.
What the trial showed
From ATTAIN-1, Lilly's pivotal trial:2
In the ATTAIN-1 trial, individuals taking the highest dose of Foundayo and who stayed on treatment lost an average of 27.3 pounds (12.4%) compared to 2.2 pounds (0.9%) with placebo.
Eli Lilly
Average weight loss at the highest dose over the trial, against 0.9% on placebo. Read it beside the injectables rather than in isolation: this is a pill, and it lands below what tirzepatide achieves by injection.
Note the conditions in that sentence, because they are doing work: highest dose and stayed on treatment. It is the best case, not the average experience of everyone who started.
The pricing runs backwards here
This is the part that surprised us. Lilly publishes:1
starting at $25 per month with commercial coverage and $149 for self-pay
Eli Lilly
Now put that against what the telehealth programs we track actually charge for it, all-in with their membership fees included:
| Route | All-in per month |
|---|---|
| Lilly direct, self-pay, lowest dose | $149 |
| Maximus | $199.99 |
| Sesame Care | $208 |
| Ro | $223 |
Seller prices read on 28 August 2026, membership fees included. They move, and the ranking further down is the live version; Lilly’s published figure is the one that has stayed put.
On that reading the manufacturer is the cheapest route, and by a clear margin. On this site that is close to unheard of: for semaglutide and tirzepatide the compounded telehealth market undercuts the brand by hundreds of dollars a month, which is most of why the board exists.
The reason is worth understanding rather than memorising. Orforglipron is a new small molecule under patent, so there is no compounded version of it and there cannot legally be one. Nothing exists to undercut the brand, so the brand sets the floor. Every cheap compounded price you have seen in this category is semaglutide or tirzepatide, and none of it applies here.
Two honest caveats on that table. Lilly's $149 is the lowest dose; their published ladder rises to $199 and then $299 as you titrate up. And the telehealth figures are entry prices that bundle the prescribing visit, so check what happens to yours as the dose climbs before assuming a flat line.
Will insurance cover it?
Partly, and the answer has the same shape as every other weight-loss drug.
Anthem's 2026 drug list is the clearest artefact we have found on this. Foundayo is there, at Tier 2, with three note codes:5
FOUNDAYO ORAL TABLET | 2 | PA; BE; QL … BE = benefit exclusion. This drug may not be covered depending on your plans design.
Anthem
So a listing at a good tier, and a flag saying your employer decides whether that listing means anything for you. On the same document, Ozempic and Mounjaro carry no such flag, because they are diabetes drugs. That contrast is the whole coverage system in one line.
On Medicare there is a real route, and Foundayo is named first in it:6
Starting July 1, 2026, the Medicare GLP-1 Bridge program will give eligible Part D plan members access to Foundayo, Wegovy (injection or tablet), or Zepbound (KwikPen) weight loss medications for a $50 copayment for each 30-day supply.
Humana
With commercial insurance, Lilly's savings card advertises as little as $25 a month.4 The usual caution applies: manufacturer cards reduce a copay rather than setting your price, and government beneficiaries are excluded. What the cards are actually worth covers the arithmetic.
So who is it for
- Anyone who will not inject. That is the honest headline. A meaningful number of people never start a GLP-1 for this reason alone.
- Anyone who failed the semaglutide pill ritual rather than the drug. No fasting window here.
- Medicare beneficiaries, given the Bridge covers it at $50 and it is named first on that list.
- Not the price-minimising shopper. If cost is the only axis, compounded injectable semaglutide or tirzepatide is far cheaper, and it is not close.
If you want the full landscape of swallowable options, every GLP-1 pill compared puts Foundayo beside the three semaglutide tablets. If your plan says no, which kind of no you got decides what to do next, and our coverage tracker carries the verified position for eight insurers.